Therapeutic assessment of synthetic heparin sulfates in transplantation models
移植模型中合成硫酸肝素的治疗评估
基本信息
- 批准号:8669117
- 负责人:
- 金额:$ 34.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AdhesionsAdhesivesAdverse effectsAntibodiesAnticoagulantsAnticoagulationAntigensArteriesBindingBiological AssayBiologyBloodBlood Coagulation DisordersBlood Coagulation FactorBlood PlateletsCellsChemicalsChemistryChemotaxisClinical TrialsCoagulation ProcessComplementComputer SimulationDataData AnalysesDefectDevelopmentFaceFactor XaFamily suidaeGenesGeneticGenetic EngineeringGlycosaminoglycansGraft SurvivalHemoperfusionHemorrhageHeparinHeparitin SulfateHourHumanIn VitroInflammationInflammatoryInjuryInorganic SulfatesInstructionInterventionKidneyLeukocytesLungMeasuresMediatingModelingModificationMolecularMolecular TargetMonitorOrganOrgan TransplantationPapioPathway interactionsPlasmaPlatelet Activating FactorPlatelet ActivationPlayPrimatesProductionRelative (related person)RoleSite-Directed MutagenesisSourceT cell responseT-LymphocyteTechnologyTestingTherapeuticTherapeutic immunosuppressionThrombinThrombomodulinTransplantationUnspecified or Sulfate Ion SulfatesXenograft procedurebasechemokineclinical applicationcytokinedesigndosagedrug candidategenetic manipulationgraft functionimmunosuppressedin vitro Assayin vivoinhibitor/antagonistmonocyteneutrophilnovel therapeuticspreventprothrombinase complexresearch studyscreeningtoolvascular inflammation
项目摘要
Despite significant advances in pig-to-primate organ xenotransplantation, long-term graft survival is
currently limited by the development of a thrombotic microangiopathy and platelet sequestration in the
grafted organ and/or a consumptive coagulopathy in the recipient. The present proposal tests homogeneous
heparin sulfates (HSs) synthesized using computational modeling and enzymatic/chemical tools as outlined
in Projects I (PL-I. Dr. Balagurunathan) and II (Pl-ll. Dr. Desai). We hypothesize that chemically-synthesized
HSs designed to preferentially inhibit Factor Xa (FXa) and/or thrombin will ameliorate the thrombotic
microangiopathy and/or consumptive coagulopathy seen in the context of pig-to-primate xenografts by
inhibiting thrombin formation and platelet activation. In addition, HSs optimized to bind chemokines (from
Project III) may act as chemokine decoy factors to prevent cell sequestration synergistically with
anticoagulation. These HSs will be evaluated in the context of various xenotransplantation models using
cells and organs from pigs genetically modified to protect against antibody/complement-mediated,
inflammatory, and coagulation rejection mechanisms. These HS-based therapies will be tested by. - (i) in
vitro assays to determine the best HS candidate drugs for further studies, (ii) ex vivo pig lung hemoperfusion
using human blood, (iii) pig artery Tx in baboons, and (iv) pig kidney Tx in baboons. Model (ii) constitutes a
short-duration model (with graft function measured in hours) allowing rapid screening of the HSs being
tested, whereas models (iii) and (iv) constitute longer-duration models (days or weeks). Furthermore, the
effect of the HS will be monitored (iii) in a low-antigen load model without immunosuppressive therapy, or (iv)
in a high-antigen load model in which graft recipients will receive immunosuppressive therapy aimed at
inhibiting the adaptive T cell response. The prime aim of the study is to identify one (or more) HS that is
more specific and more efficient at inhibiting the development of thrombotic microangiopathy and
consumptive coagulopathy than is the current clinically-used heparin, and that, furthermore, is not associated
with the side-effects of heparin, e.g., bleeding, that limit the dosage that can be administered. The second
aim is to investigate the synergy between the HS identified as being optimal with the genetic manipulations
in the organ-source pig, e.g., expression of human thrombomodulin directed towards inhibiting thrombotic
microangiopathy and consumptive coagulopathy.
RELEVANCE (See instructions):
The transplantation of organs from genetically-engineered pigs would provide an alternative source to
human organs for clinical transplantation, but is currently complicated by coagulation disturbances that can
be fatal. The administration of specific synthetic heparan sulfates that will be designed and investigated in
this proposal are likely to prevent these coagulation disturbances, thus enabling xenotransplantation to
advance to clinical trials.
尽管猪到灵长类动物器官异种移植取得了重大进展,
目前受到血栓性微血管病和血小板隔离的限制,
移植器官和/或消耗性凝血病。目前的建议测试同质
使用所述的计算建模和酶/化学工具合成硫酸肝素(HS)
在项目I(PL-I. Balagurunathan)和II(Pl-II. Desai博士)。我们假设化学合成的
被设计为优先抑制因子Xa(FXa)和/或凝血酶的HS将改善血栓形成。
在猪至灵长类动物异种移植物中观察到的微血管病和/或消耗性凝血病,
抑制凝血酶形成和血小板活化。此外,HS被优化以结合趋化因子(来自
项目III)可以作为趋化因子诱饵因子,与
抗凝这些HS将在各种异种移植模型的背景下进行评价,
来自猪的细胞和器官经遗传修饰以保护免受抗体/补体介导的,
炎症和凝血排斥机制。这些基于HS的治疗将由进行检测。- (i)在
体外测定以确定用于进一步研究的最佳HS候选药物,(ii)离体猪肺血液灌流
使用人血,(iii)狒狒中的猪动脉Tx,和(iv)狒狒中的猪肾Tx。模型(二)构成了
短期模型(以小时为单位测量移植物功能)允许快速筛选HS,
模型(iii)和(iv)构成了持续时间较长的模型(天或周)。而且
将监测HS的作用(iii)在无免疫抑制治疗的低抗原负荷模型中,或(iv)
在高抗原负荷模型中,移植受体将接受免疫抑制治疗,
抑制适应性T细胞反应。该研究的主要目的是确定一个(或多个)HS,
在抑制血栓性微血管病的发展方面更特异和更有效,
消耗性凝血病比目前临床上使用的肝素,而且,此外,
由于肝素的副作用,例如,出血,这限制了可以施用的剂量。第二
目的是研究鉴定为最佳的HS与遗传操作之间的协同作用
在器官源猪中,例如,针对抑制血栓形成的人血栓调节蛋白的表达
微血管病和消耗性凝血病。
相关性(参见说明):
从基因工程猪身上移植器官将提供一个替代来源,
用于临床移植的人体器官,但目前因凝血障碍而复杂化,
是致命的。具体的合成硫酸乙酰肝素的管理,将设计和研究,
这一建议可能会防止这些凝血障碍,从而使异种移植,
推进临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID KC COOPER其他文献
DAVID KC COOPER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID KC COOPER', 18)}}的其他基金
Alemtuzumab and Regulatory T Cells for Heart Transplant Tolerance in Monkeys
阿仑单抗和调节性 T 细胞对猴子心脏移植耐受的影响
- 批准号:
8111828 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
Genetically-engineered pig organ transplantation into nonhuman primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
8116016 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
Genetically-engineered pig organ transplantation into nonhuman primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
8711224 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
Genetically-engineered pig kidney transplantation in baboons: reducing the adaptive immune response and monitoring graft function
狒狒基因工程猪肾移植:降低适应性免疫反应并监测移植物功能
- 批准号:
10019098 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
Genetically-engineered pig organ transplantation in baboons: immunological and functional studies
狒狒基因工程猪器官移植:免疫学和功能研究
- 批准号:
10621195 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
Genetically-engineered Pig Organ Transplantation into Non-human Primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
9115981 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
Alemtuzumab and Regulatory T Cells for Heart Transplant Tolerance in Monkeys
阿仑单抗和调节性 T 细胞对猴子心脏移植耐受的影响
- 批准号:
8487350 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
Genetically-engineered pig organ transplantation into nonhuman primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
8309417 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
Genetically-engineered pig organ transplantation into nonhuman primates
基因工程猪器官移植到非人类灵长类动物中
- 批准号:
7997529 - 财政年份:2010
- 资助金额:
$ 34.44万 - 项目类别:
相似海外基金
I-Corps: Translation Potential of Peptidic Ensembles as Novel Bio-adhesives
I-Corps:肽整体作为新型生物粘合剂的转化潜力
- 批准号:
2409620 - 财政年份:2024
- 资助金额:
$ 34.44万 - 项目类别:
Standard Grant
Architectural design of active adhesives
活性粘合剂的结构设计
- 批准号:
2403716 - 财政年份:2024
- 资助金额:
$ 34.44万 - 项目类别:
Standard Grant
Design of non-swellable adhesives for brain surgery using cyclodextrin inclusion polymer
使用环糊精包合物聚合物脑外科不可溶胀粘合剂的设计
- 批准号:
23H01718 - 财政年份:2023
- 资助金额:
$ 34.44万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Meta-material adhesives for improved performance and functionalisation of bondlines
超材料粘合剂可提高粘合层的性能和功能化
- 批准号:
EP/W019450/1 - 财政年份:2023
- 资助金额:
$ 34.44万 - 项目类别:
Fellowship
Light-propelled dental adhesives with enhanced bonding capability
具有增强粘合能力的光驱动牙科粘合剂
- 批准号:
10741660 - 财政年份:2023
- 资助金额:
$ 34.44万 - 项目类别:
DMREF: Accelerating the Design of Adhesives with Nanoscale Control of Thermomechanical Properties
DMREF:通过热机械性能的纳米级控制加速粘合剂的设计
- 批准号:
2323317 - 财政年份:2023
- 资助金额:
$ 34.44万 - 项目类别:
Continuing Grant
Mag-Cure: A novel method for magnetically induced bonding and de-bonding of thermoset adhesives in the Automotive Industry
Mag-Cure:汽车行业中热固性粘合剂磁感应粘合和脱粘的新方法
- 批准号:
10062336 - 财政年份:2023
- 资助金额:
$ 34.44万 - 项目类别:
Collaborative R&D
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
- 批准号:
10677869 - 财政年份:2022
- 资助金额:
$ 34.44万 - 项目类别:
Poly(glycerol carbonate) pressure sensitive adhesives for the in vivo closure of alveolar pleural fistulae
用于体内闭合肺泡胸膜瘘的聚(甘油碳酸酯)压敏粘合剂
- 批准号:
10746743 - 财政年份:2022
- 资助金额:
$ 34.44万 - 项目类别:
Enhanced bio-production of difficult to make peptide ingredients for specialty adhesives and personal care
增强用于特种粘合剂和个人护理品的难以制造的肽成分的生物生产
- 批准号:
10021363 - 财政年份:2022
- 资助金额:
$ 34.44万 - 项目类别:
Investment Accelerator